Key result
Higher corticosteroid dose linked to ~3% greater risk of physical performance decline post-HSCT.
Why the study?
This study aimed to prospectively investigate the factors affecting the diminished ability of patients to stand up following hematopoietic stem cell transplantation.
Does total corticosteroid dose predict physical performance decline in patients undergoing HSCT?
Cohort (n=50)
Does total corticosteroid dose predict physical performance decline in patients undergoing HSCT?
Effect estimate: OR 1.03 (95% CI 1.00-1.05)
Higher total corticosteroid dose is independently associated with a decline in physical performance, specifically the ability to stand up, following hematopoietic stem cell transplantation.
Corticosteroid minimization may help preserve physical function after HSCT; this small observational link leaves open the need for randomized confirmation.
Objectives: This study aimed to prospectively investigate the factors affecting the diminished ability of patients to stand up following hematopoietic stem cell transplantation (HSCT). Methods: Fifty patients were enrolled in the study. Pre- and post-HSCT physical performance was assessed using the Short Physical Performance Battery (SPPB). Post-HSCT physical performance decline was defined as a decrease of at least 1 point in the SPPB chair rise score at hospital discharge compared with the pre-HSCT score. Factors associated with this decline were analyzed using multiple logistic regression. Results: A functional decline in the ability to stand up post-HSCT was noted. The total corticosteroid dose (odds ratio, 1.03, 95% confidence interval 1.00-1.05) showed an independent association with physical performance decline post-HSCT. Conclusions: The total corticosteroid dose is a valuable predictor of physical performance decline post-HSCT. Therefore, standing up movements should be evaluated cautiously in patients who are expected to receive high corticosteroid doses for the treatment of acute graft-versus-host disease or HSCT regimens.
No takes yet. Share an insight, caveat, or question.
Nishikado et al. (2026) conducted a cohort in Hematopoietic stem cell transplantation (HSCT) (n=50). Total corticosteroid dose was evaluated on Decrease of at least 1 point in the SPPB chair rise score at hospital discharge compared with the pre-HSCT score (OR 1.03, 95% CI 1.00-1.05). Higher total corticosteroid dose was independently associated with a decline in physical performance post-HSCT (OR 1.03; 95% CI 1.00-1.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: